FREMONT, Calif., Oct. 25 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(PDL) (Nasdaq: PDLI) today announced that it will release its financial
results for the third quarter 2006 following the close of the U.S.
financial markets on Thursday, November 2, 2006. PDL will hold a conference
call to discuss these financial results, its commercial and clinical
activities and its forward-looking information and guidance at 4:30 p.m.
Eastern time on November 2, 2006.
A live webcast of the conference call will be available through the PDL
website: http://www.pdl.com . Please connect to this website at least 15 minutes
prior to the live webcast to allow time for any software download that may
be needed to hear the webcast. Financial and statistical information to be
discussed in the call will be available on the PDL website immediately
prior to the commencement of the call. A replay will be available at
http://www.pdl.com starting approximately one hour after completion of the
webcast.
An audio replay will also be available by telephone from approximately
6:30 p.m. Eastern time on November 2, 2006 through 6:30 p.m. Eastern time
on December 3, 2006. To access the replay, dial 888-203-1112 from inside
the U.S. and 719-457-0820 from outside the U.S.; enter conference ID number
2444267.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for severe
or life-threatening illnesses. The company currently markets and sells a
portfolio of leading products in the acute-care hospital setting in the
United States and Canada and generates royalties through licensing
agreements with top-tier biotechnology and pharmaceutical companies based
on its pioneering antibody humanization technology. Currently, PDL's
diverse product pipeline includes investigational compounds in Phase 2 or
Phase 3 clinical development for inflammation and autoimmune diseases,
cardiovascular disorders and cancer. The company's research platform is
focused on the discovery and development of antibodies for the treatment of
cancer and autoimmune diseases. For more information, please see PDL's
website at http://www.pdl.com .
NOTE: PDL BioPharma and the PDL BioPharma logo are considered
trademarks of PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
Ami Knoefler, Corporate and Investor
Relations of PDL BioPharma, Inc., +1-510-284-8851, or
ami.knoefler@pdl.com
|
